Periodic Reporting for period 1 - HepaCheC (HepaCheC - an in vitro diagnostic assay for the early detection of liver cancer)
Reporting period: 2018-02-01 to 2018-07-31
The feasibility study was performed through:
- Discussions with key opinion leaders (KOLs)/clinicians within the hepatocellular carcinoma (HCC) field re-garding clinical praxis, surveillance, diagnosis and follow-up.
- Review of HCC guidelines in different countries (where available and relevant for us).
- Review of published articles (peer-reviewed journals) of relevance for HCC aetiology, spread, surveillance and diagnosis. PubMed and Google were the main search engines used.
- Discussions with large diagnostic companies with an interest in HCC surveillance/diagnosis to find out their degree of interest for incorporating a new diagnostic tool for HCC diagnosis into their analysis platforms.
- Contact with distributors of diagnostic kits and related equipment.
The HepaCheC assay, on the other hand, is a minimally invasive method (requiring a blood sample) with high selectivity and specificity that detects a specific liver cancer biomarker; fucosylated AGP (α1-acid glycoprotein). Glycobond’s patented Mono-F peptide constitutes the solid phase of the HepaCheC assay, followed by an in-house developed polyclonal AGP-specific antibody. The assay is based on the ELISA methodology, making it easily incorporated into the workflow of any standard diagnostic/research laboratory requiring only elementary laboratory know-how to be performed. The goal of Glycobond is to make HepaCheC part of the existing surveillance guidelines that are in place to monitor high-risk patients in the EU, US and Japan. If successful, the company will increase its international competitiveness and experience accelerated growth.